Jeil Pharma Holdings Inc
Symbol: 002620.KS
KSC
10560
KRWDzisiejsza cena rynkowa
-20.3172
Wskaźnik P/E
0.0956
Wskaźnik PEG
162.11B
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Jeil Pharma Holdings Inc (002620-KS) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 234375.12 | 59131 | 53402.7 | 47223.7 | |||||||||||||||||
balance-sheet.row.short-term-investments | 86457.8 | 22092.4 | 18643.2 | 18642.9 | |||||||||||||||||
balance-sheet.row.net-receivables | 782964.19 | 198695.1 | 181304.5 | 167949 | |||||||||||||||||
balance-sheet.row.inventory | 531549.74 | 125280.1 | 113265.7 | 114242.9 | |||||||||||||||||
balance-sheet.row.other-current-assets | 11507.57 | 1421 | 4943.5 | 5728.2 | |||||||||||||||||
balance-sheet.row.total-current-assets | 1560396.62 | 384527.2 | 352916.4 | 335143.7 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 921883.08 | 228862.4 | 233120.1 | 212965.1 | |||||||||||||||||
balance-sheet.row.goodwill | 265259.92 | 44862.3 | 73465.9 | 151801.2 | |||||||||||||||||
balance-sheet.row.intangible-assets | 48297.94 | 13093.2 | 9472.3 | 3781.3 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 313557.86 | 57955.5 | 82938.2 | 155582.5 | |||||||||||||||||
balance-sheet.row.long-term-investments | 389896.62 | 199929.7 | 67118.8 | 60379.6 | |||||||||||||||||
balance-sheet.row.tax-assets | -64449.59 | 5448.7 | 188.5 | 1451.9 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 470872.57 | 3273.5 | 129395.1 | 126898.6 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 2031760.54 | 495469.8 | 512760.6 | 557277.7 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 3592157.16 | 879997 | 865677 | 892421.4 | |||||||||||||||||
balance-sheet.row.account-payables | 636258.45 | 154050 | 162967.4 | 159388.3 | |||||||||||||||||
balance-sheet.row.short-term-debt | 600673.06 | 161332.5 | 119087.3 | 94964.5 | |||||||||||||||||
balance-sheet.row.tax-payables | 3382.6 | 774.7 | 1159.8 | 684.8 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 49892.41 | 10500 | 17477 | 20107.5 | |||||||||||||||||
Deferred Revenue Non Current | 9246.16 | 1198 | 0 | 36229.2 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 145216.43 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 205023.86 | 95305.2 | 74662 | 17971.9 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 262882.12 | 65175.1 | 87379.8 | 94084.1 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 6892.95 | 1198 | 1869.2 | 2383.2 | |||||||||||||||||
balance-sheet.row.total-liab | 1882055.08 | 477810.9 | 445884.6 | 392107.7 | |||||||||||||||||
balance-sheet.row.preferred-stock | 43492.24 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 31946.71 | 7986.7 | 7986.7 | 7986.7 | |||||||||||||||||
balance-sheet.row.retained-earnings | 309763.33 | -14357.5 | 98244.6 | 172151.3 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 477369.96 | 152732.4 | 226471 | 226109.7 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 498974.16 | 173099.5 | 5062.4 | 5482.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 1361546.4 | 319461.2 | 337764.7 | 411730.5 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3592157.16 | 879997 | 865677 | 892421.4 | |||||||||||||||||
balance-sheet.row.minority-interest | 348555.67 | 82724.9 | 82027.8 | 88583.2 | |||||||||||||||||
balance-sheet.row.total-equity | 1710102.08 | 402186.1 | 419792.5 | 500313.7 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3592157.16 | - | - | - | |||||||||||||||||
Total Investments | 476354.42 | 222022.1 | 85761.9 | 79022.5 | |||||||||||||||||
balance-sheet.row.total-debt | 651763.51 | 173030.5 | 136564.4 | 115072 | |||||||||||||||||
balance-sheet.row.net-debt | 503846.19 | 135991.9 | 101804.9 | 86491.2 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -11642.57 | -16249.7 | -83145 | -12870 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 12556.11 | 12556.1 | 10905.1 | 8983.2 | |||||||||||||||||
cash-flows.row.deferred-income-tax | -8558.55 | -60632 | 0 | -664 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 578.03 | 578 | 472.5 | 163.2 | |||||||||||||||||
cash-flows.row.change-in-working-capital | -28544.09 | -28544.1 | -22115.2 | 14405.2 | |||||||||||||||||
cash-flows.row.account-receivables | -12922.7 | -12922.7 | -14120.2 | 8024.7 | |||||||||||||||||
cash-flows.row.inventory | -12170.48 | -12170.5 | 1347.3 | 9341.5 | |||||||||||||||||
cash-flows.row.account-payables | -9848.6 | -9848.6 | 3357.5 | 10023.5 | |||||||||||||||||
cash-flows.row.other-working-capital | 6397.69 | 6397.7 | -12699.8 | -12984.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 31195.44 | 87876.1 | 73080.5 | 3385.4 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -4415.63 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -9909.58 | -9836.6 | -21410 | -23736.1 | |||||||||||||||||
cash-flows.row.acquisitions-net | 87.64 | 87.6 | 24 | -1500 | |||||||||||||||||
cash-flows.row.purchases-of-investments | -3775.84 | -3769.8 | -0.3 | -10005.3 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 169.7 | 999.5 | |||||||||||||||||
cash-flows.row.other-investing-activites | 172.76 | 93.8 | 3652.9 | 41567.1 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -13425.02 | -13425 | -17563.7 | 7325.1 | |||||||||||||||||
cash-flows.row.debt-repayment | -31854.19 | -22634.4 | -5156.3 | -6125 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 7497.6 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -397 | -31210.2 | |||||||||||||||||
cash-flows.row.dividends-paid | -362 | -1133.9 | -1474.9 | -1590 | |||||||||||||||||
cash-flows.row.other-financing-activites | 54328.13 | 44384.3 | 51942.1 | 19190 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 20616.07 | 20616.1 | 44914 | -12237.6 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -496.29 | -496.3 | -369.4 | -93.2 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 2279.12 | 2279.1 | 6178.7 | 8397.4 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 147917.32 | 37038.6 | 34759.5 | 28580.8 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 145638.2 | 34759.5 | 28580.8 | 20183.4 | |||||||||||||||||
cash-flows.row.operating-cash-flow | -4415.63 | -4415.6 | -20802.2 | 13403.1 | |||||||||||||||||
cash-flows.row.capital-expenditure | -9909.58 | -9836.6 | -21410 | -23736.1 | |||||||||||||||||
cash-flows.row.free-cash-flow | -14325.21 | -14252.3 | -42212.2 | -10333.1 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 801550.85 | 794713.6 | 792964.7 | 762568.1 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 590068.68 | 592891.6 | 612481.6 | 582061.3 | |||||||||||||||||
income-statement-row.row.gross-profit | 211482.17 | 201822 | 180483.1 | 180506.8 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 45642.2 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 43332.62 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 37213.16 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 20406.32 | 4200.9 | 67032.4 | 63480.2 | |||||||||||||||||
income-statement-row.row.operating-expenses | 193054.13 | 190231.2 | 188031.1 | 189481.7 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 783122.82 | 783122.8 | 800512.7 | 771542.9 | |||||||||||||||||
income-statement-row.row.interest-income | 1731.42 | 1731.4 | 499.5 | 247.7 | |||||||||||||||||
income-statement-row.row.interest-expense | 10672.11 | 10672.1 | 5952.3 | 3288.7 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 37213.16 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -34901.84 | -34901.8 | -76312.7 | -7682.1 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 20406.32 | 4200.9 | 67032.4 | 63480.2 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -34901.84 | -34901.8 | -76312.7 | -7682.1 | |||||||||||||||||
income-statement-row.row.interest-expense | 10672.11 | 10672.1 | 5952.3 | 3288.7 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 15380.48 | 12556.1 | -63218.7 | 8983.2 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 34548.17 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 18428.04 | 11590.8 | -7548 | 1552.9 | |||||||||||||||||
income-statement-row.row.income-before-tax | -16473.8 | -23311 | -83860.6 | -6129.2 | |||||||||||||||||
income-statement-row.row.income-tax-expense | -740.82 | -740.8 | -715.6 | 6740.8 | |||||||||||||||||
income-statement-row.row.net-income | -7978.87 | -16249.7 | -83145 | -12870 |
Często zadawane pytania
Ile wynosi Jeil Pharma Holdings Inc (002620.KS) aktywów ogółem?
Jeil Pharma Holdings Inc (002620.KS) całkowite aktywa to 879996990707.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 395204780875.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.264.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to -933.170.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to -0.010.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.023.
Co to jest Jeil Pharma Holdings Inc (002620.KS) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi -16249744239.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 173030541501.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 190231187725.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 37038628042.000.